15:56 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Kleo raises $21M series B to advance to clinic in 2020

Immuno-oncology company Kleo Pharmaceuticals Inc. (New Haven, Conn.) raised $21 million in an untranched series B round on Nov. 13 to propel its next-generation Antibody Recruiting Molecules (ARMs) into the clinic by 2020. The round...
23:28 , Feb 26, 2018 |  BC Extra  |  Company News

Management tracks: Vertex, Basilea

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said CMO and EVP of Global Medicines Development and Medical Affairs Jeffrey Chodakewitz will retire, effective April 1. He is succeeded by Vertex SVP of Clinical Development and Medical Affairs Reshma...
20:18 , Jan 12, 2018 |  BC Extra  |  Company News

Management tracks: Ipsen, PeptiDream

Ipsen Group (Euronext:IPN; Pink:IPSEY) said President of Ipsen North America Cynthia Schwalm is stepping down. She is succeeded by Richard Paulson as EVP and CEO, effective Feb 5. He was VP and general manager of...
23:34 , Nov 30, 2017 |  BC Extra  |  Company News

Bayer reorganizes R&D

Bayer AG (Xetra:BAYN) said Thursday it will consolidate its R&D into one unit led by Jörg Möller. Möller, the head of development of the company’s pharmaceutical division, will become head of R&D, effective Jan. 1....
20:03 , Nov 17, 2017 |  BC Week In Review  |  Company News

PeptiDream identifying peptide candidates against Bayer targets

Bayer AG (Xetra:BAYN) and PeptiDream Inc. (Tokyo:4587) partnered to use PeptiDream's Peptide Discovery Platform System to identify macrocyclic peptide candidates against cancer and cardiovascular disease targets from Bayer. The pharma will also have an option...
00:09 , Nov 17, 2017 |  BC Extra  |  Company News

FDA committee votes no on Bayer's inhaled Cipro

FDA’s Antimicrobial Drugs Advisory Committee voted against approval of Cipro ciprofloxacin inhalation powder from Bayer AG (Xetra:BAYN) to reduce exacerbations in adults with non-cystic fibrosis bronchiectasis and bacterial respiratory pathogens. The committee voted 9-6 and...
19:51 , Aug 4, 2017 |  BC Week In Review  |  Company News

Kleo, Peptidream partner to discover and develop immunotherapeutics

PeptiDream Inc. (Tokyo:4587) and Kleo Pharmaceuticals Inc. (New Haven, Conn.) partnered to develop immunotherapeutics. Peptidream will use its Peptide Discovery Platform System to identify and optimize macrocyclic/constrained peptides against cancer targets selected by Kleo. Kleo...
20:30 , Jun 16, 2017 |  BC Week In Review  |  Company News

PeptiDream grants Shionogi non-exclusive license to its PDPS peptide discovery technology

Shionogi & Co. Ltd. (Tokyo:4507) gained a non-exclusive license from PeptiDream Inc. (Tokyo:4587) to use its Peptide Discovery Platform System (PDPS) technology to discover macrocyclic and constrained peptides for any target or indication. PeptiDream said...
16:33 , Apr 14, 2017 |  BC Week In Review  |  Company News

PeptiDream, J&J deal

PeptiDream and Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit partnered to discover and optimize macrocyclic/constrained peptides against undisclosed metabolic and cardiovascular targets provided by Janssen using PeptiDream’s Peptide Discovery Platform System (PDPS) technology. Janssen has...
21:33 , Feb 24, 2017 |  BC Week In Review  |  Company News

PeptiDream, Daiichi Sankyo deal

Daiichi selected the first development candidate under a 2012 deal with PeptiDream to discover macrocyclic and constrained peptides against Daiichi targets using the biotech’s Peptide Discovery Platform System (PDPS). Daiichi will have exclusive, worldwide rights...